IDEAYA Biosciences
IDYA
25.56
-0.61
-2.33%
IDEAYA Biosciences
US · IDYA
#2357 by market cap
Listed 2019
25.56
-0.61
-2.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62Market Newswire · 2026/8/11
-
Rating change
William Blair Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51Market Newswire · 2026/10/16
-
Rating change
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60Market Newswire · 2026/10/27
-
Rating change
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/10/28
-
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $39Market Newswire · 2026/11/10
-
Rating change
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $57Market Newswire · 2026/11/4
-
Rating change
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/9/28
-
Rating change
Citizens JMP Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $42Market Newswire · 2026/8/7
-
Rating change
Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $57Market Newswire · 2026/9/9
-
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $63Market Newswire · 2026/11/4
-
Rating change
Stifel Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $48Market Newswire · 2026/10/14
-
Rating change
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $44Market Newswire · 2026/10/29
-
Rating change
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy RatingMarket Newswire · 2026/9/1
-
Rating change
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/9/1
-
Rating change
Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/9/11
-
Rating change
UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/10/28
-
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $45Market Newswire · 2026/11/4
-
Rating change
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/10/26
-
Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $52Market Newswire · 2026/11/4
-
Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $66Market Newswire · 2026/11/5
-
Rating change
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62Market Newswire · 2026/7/27
-
Rating change
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63Market Newswire · 2026/7/7
-
Rating change
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $60Market Newswire · 2026/8/6
-
Rating change
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59Market Newswire · 2026/8/5
-
Rating change
Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (CVKD) and IDEAYA Biosciences (IDYA)TipRanks · 2026/6/16
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
IDEAYA Biosciences discussion 0 comments